Global Blood Therapeutics, Inc. GBT
Day range unavailable
52-week range unavailable
- Market cap
- 4.62B
- Revenue (ttm)
- 234.86M
- Profit margin
- -137.30%
- Shares out
- 67.48M
- Forward P/E
- -29.14
- Beta
- 0.46
- Analysts
- Buy
- Price target
- 64.50 (-5.8%)
- Earnings date
- Nov 3, 2022
2Y +29.12 (+73.96%)
Key statistics
- Enterprise value
- 4.76B
- PEG ratio
- -0.44
- Price / sales
- 19.68
- Price / book
- 38.94
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 50.50%
- Free cash flow
- -134.82M
- Total cash
- 517.16M
- Total debt
- 658.39M
- Return on equity
- -148.56%
- Short % of float
- 11.05%
- 50-day average
- 63.70
- 200-day average
- 38.56
Analyst view
Consensus: buy
- Target (low)
- 60.00
- Target (mean)
- 64.50
- Target (high)
- 68.50
- Strong buy4
- Buy8
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 3, 2022
Expected Nov 3, 2022. Consensus EPS estimate -1.06.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2022 | Sep 1, 2022 | -1.16 | — | — | — |
| Aug 8, 2022 | Jun 1, 2022 | -1.19 | — | — | — |
| May 4, 2022 | Mar 1, 2022 | -1.29 | — | — | — |
| Feb 23, 2022 | Dec 1, 2021 | -1.14 | — | — | — |
| Nov 4, 2021 | Sep 1, 2021 | -1.10 | — | — | — |
| Aug 3, 2021 | Jun 1, 2021 | -1.17 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 9, 2022 | RBC Capital | down | Outperform | Sector Perform |
| Aug 9, 2022 | Wells Fargo | down | Overweight | Equal-Weight |
| Aug 9, 2022 | SVB Leerink | down | Outperform | Market Perform |
| Aug 19, 2022 | Cantor Fitzgerald | down | Overweight | Neutral |
| Aug 9, 2022 | Cowen & Co. | down | Outperform | Market Perform |
| Aug 8, 2022 | Stifel | down | Buy | Hold |
About Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- gbt.com
News
BMTC Group (TSE:GBT) Stock Price Crosses Below 50-Day Moving Average – What’s Next? 
Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals 
GLOBAL BLOOD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Global Blood Therapeutics, Inc. - GBT 
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates AAWW, GBT, CYBE, AVLR 
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GBT, AVLR, CYBE, SBCF 
Get ready for more merger mania in pharma sector the rest of the year 
Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings 
Pfizer is acquiring Global Blood Therapeutics 
Pfizer to buy Global Blood Therapeutics for US$5.4bn 
SHAREHOLDER ALERT: Weiss Law Investigates Global Blood Therapeutics, Inc.
Your note
Sign in to keep a note on GBT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHOI JUNG E. | Officer | Stock Gift | Sep 28, 2022 | 251,672 |
| FARROW JEFFREY S | Chief Financial Officer | Conversion of Exercise of derivative security | Sep 26, 2022 | 26,739 |
| HABIBIZAD NAZILA | Officer | Conversion of Exercise of derivative security | Sep 26, 2022 | 41,623 |
| JOHNSON DAVID LEE | Chief Operating Officer | Conversion of Exercise of derivative security | Aug 31, 2022 | 56,384 |
| KREHLIK CARRIE | Officer | Conversion of Exercise of derivative security | Aug 31, 2022 | 6,716 |
| LOVE TED WENDELL | Chief Executive Officer | Conversion of Exercise of derivative security | Sep 26, 2022 | 802,968 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 8.92% | 6,019,431 | 412.27M | Jun 29, 2022 |
| Blackrock Inc. | 7.07% | 4,772,391 | 326.86M | Jun 29, 2022 |
| Janus Henderson Group PLC | 6.64% | 4,478,248 | 306.72M | Jun 29, 2022 |
| State Street Corporation | 6.56% | 4,423,544 | 302.97M | Jun 29, 2022 |
| Baker Brothers Advisors, LLC | 5.53% | 3,732,502 | 255.64M | Jun 29, 2022 |
| Deep Track Capital, LP | 5.40% | 3,646,690 | 249.76M | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 4.50% | 3,034,375 | 207.82M | Aug 30, 2022 |
| Vanguard Total Stock Market Index Fund | 2.84% | 1,914,662 | 131.14M | Jun 29, 2022 |
| Vanguard Small-Cap Index Fund | 2.43% | 1,637,261 | 112.14M | Jun 29, 2022 |
| iShares Russell 2000 ETF | 2.00% | 1,347,913 | 92.32M | Aug 30, 2022 |
| Janus Henderson Global Life Sciences Fund | 1.53% | 1,030,590 | 70.59M | Jun 29, 2022 |
| Vanguard Small-Cap Growth Index Fund | 1.44% | 969,336 | 66.39M | Jun 29, 2022 |